NeuroSpectrum Insights ^{Filed, US Offering, NYSE: NSI.RC}

We are a medical device company preparing to commercialize breakthrough computerized analysis technology that enhances clinicians’ capabilities in diagnosing neurological and neurodevelopmental disorders. NSI’s first product, GyriCalc is a proprietary, patented software solution specifically designed to assist in the diagnosis of autism by identifying early structural markers of neurodevelopmental differences through the automated analysis of MRI images. NSI’s initial market focus will be the United States and Canada. In the U.S., we filed for marketing clearance with the FDA in early March 2025 and anticipate receiving approval during 2025. In Canada, where no regulatory approval is required, we recognize the political nature of the healthcare industry and will prioritize strategic discussions with influential government departments and non-profit organizations to ensure a successful market entry. Currently, NSI does not generate any revenue. Our primary focus is on successfully launching GyriCalc for autism and establishing a foothold in the U.S. and Canadian markets.